Compare Stocks: ALNY, ARGX, NTRA, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$159.85 +5.4%	$223.45	$149.18 ▼ $479.79	$20.31B	0.42	2.95 million shs	3.36 million shs
ARGX argenex	$977.58 +0.6%	$927.22	$661.85 ▼ $1,072.75	$61.10B	0.48	434,159 shs	245,638 shs
NTRA Natera	$319.82 +2.5%	$379.91	$181.00 ▼ $437.41	$45.24B	1.55	2.07 million shs	1.75 million shs
RVMD Revolution Medicines	$180.70 -6.4%	$195.89	$63.50 ▼ $224.31	$41.76B	1.44	2.26 million shs	3.26 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-3.17%	-5.16%	-34.83%	-32.29%	-65.67%
ARGX argenex	+0.96%	+7.82%	+17.76%	+10.91%	+11.69%
NTRA Natera	-2.62%	-19.72%	-22.14%	-1.26%	+50.98%
RVMD Revolution Medicines	-3.54%	-0.60%	+1.74%	-5.94%	+207.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$159.85 +5.4%	$223.45	$149.18 ▼ $479.79	$20.31B	0.42	2.95 million shs	3.36 million shs
ARGX argenex	$977.58 +0.6%	$927.22	$661.85 ▼ $1,072.75	$61.10B	0.48	434,159 shs	245,638 shs
NTRA Natera	$319.82 +2.5%	$379.91	$181.00 ▼ $437.41	$45.24B	1.55	2.07 million shs	1.75 million shs
RVMD Revolution Medicines	$180.70 -6.4%	$195.89	$63.50 ▼ $224.31	$41.76B	1.44	2.26 million shs	3.26 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-3.17%	-5.16%	-34.83%	-32.29%	-65.67%
ARGX argenex	+0.96%	+7.82%	+17.76%	+10.91%	+11.69%
NTRA Natera	-2.62%	-19.72%	-22.14%	-1.26%	+50.98%
RVMD Revolution Medicines	-3.54%	-0.60%	+1.74%	-5.94%	+207.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.65	Moderate Buy	$305.86	91.34% Upside
ARGX argenex	2.82	Moderate Buy	$1,158.76	18.53% Upside
NTRA Natera	2.83	Moderate Buy	$394.31	23.29% Upside
RVMD Revolution Medicines	2.92	Moderate Buy	$263.15	45.63% Upside

Current Analyst Ratings Breakdown

Latest ALNY, ARGX, NTRA, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	NTRA Natera	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$458.00 ➝ $403.00
11/6/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$363.50
11/6/2026	NTRA Natera	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$460.00 ➝ $405.00
11/6/2026	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$280.00 ➝ $350.00
11/5/2026	RVMD Revolution Medicines	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$250.00 ➝ $270.00
11/5/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$260.00 ➝ $321.00
11/5/2026	RVMD Revolution Medicines	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$210.00 ➝ $222.00
11/5/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$241.00 ➝ $261.00
11/5/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$275.00 ➝ $298.00
11/2/2026	ALNY Alnylam Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$450.00 ➝ $380.00
11/2/2026	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$429.00 ➝ $323.00

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	5.76	$2.95 per share	54.23	$26.91 per share	5.94
ARGX argenex	$4.25B	14.47	$21.47 per share	45.54	$118.34 per share	8.26
NTRA Natera	$2.31B	20.11	N/A	N/A	$12.89 per share	24.81
RVMD Revolution Medicines	$11.58M	3,375.10	N/A	N/A	$11.10 per share	16.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$19.26	8.30	19.64	N/A	52.85%	155.33%	44.81%	N/A
ARGX argenex	$1.29B	$28.66	34.11	27.63	0.90	31.66%	47.70%	40.12%	N/A
NTRA Natera	-$208.16M	-$1.14	N/A	N/A	N/A	-5.66%	-8.61%	-5.93%	N/A
RVMD Revolution Medicines	-$1.13B	-$9.11	N/A	N/A	N/A	N/A	-84.51%	-51.97%	N/A

Latest ALNY, ARGX, NTRA, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NTRA Natera	-$0.2810	-$0.42	-$0.1390	-$0.42	$707.54 million	$793.98 million
11/4/2026	Q3 2026	RVMD Revolution Medicines	-$2.35	-$1.90	+$0.45	-$1.90	$25.58 million	$197.56 million
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.66	$16.26	+$14.60	$15.72	$1.43 billion	$1.46 billion
10/23/2026	Q3 2026	ARGX argenex	$7.44	$7.80	+$0.36	$7.80	N/A	$1.75 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARGX argenex	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.18	2.48	2.43
ARGX argenex	N/A	5.12	4.89
NTRA Natera	N/A	2.81	2.85
RVMD Revolution Medicines	0.44	8.36	8.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARGX argenex	60.32%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
ARGX argenex	2.43%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.94 million	132.79 million	Optionable
ARGX argenex	1,863	62.89 million	61.36 million	Optionable
NTRA Natera	6,140	145.01 million	137.68 million	Optionable
RVMD Revolution Medicines	883	216.29 million	199.85 million	Optionable

ALNY, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Stock Falls 4.7% - Should You Sell?

November 11 at 1:39 PM | marketbeat.com

Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet

November 10 at 10:56 AM | zacks.com

Revolution Medicines, Inc. 2026 Q3 - Results - Earnings Call Presentation

November 10 at 7:19 AM | seekingalpha.com

HC Wainwright Has Optimistic Opinion of RVMD FY2026 Earnings

November 10 at 6:11 AM | marketbeat.com

CenterBook Partners LP Buys New Holdings in Revolution Medicines, Inc. $RVMD

November 10 at 3:47 AM | marketbeat.com

Equities Analysts Offer Predictions for RVMD FY2026 Earnings

November 9 at 1:11 AM | marketbeat.com

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

November 8 at 11:15 AM | fool.com

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

November 8 at 10:15 AM | fool.com

Revolution Medicines, Inc. $RVMD Stock: Pictet Asset Management Holding SA Cuts Holdings

November 8 at 6:04 AM | marketbeat.com

11,058 Shares in Revolution Medicines, Inc. $RVMD Purchased by Rakuten Investment Management Inc.

November 8 at 5:15 AM | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

November 8 at 4:59 AM | marketbeat.com

Revolution Medicines, Inc. $RVMD Stock: Candriam S.C.A. Trims Position

November 8 at 4:27 AM | marketbeat.com

FY2029 EPS Estimate for Revolution Medicines Cut by Analyst

November 8 at 2:48 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Now Rated "Moderate Buy" by Wall Street Analysts

November 8 at 2:13 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Raised to Hold at Wall Street Zen

November 7, 2026 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Upgraded to "Hold" at Wall Street Zen

November 7, 2026 | marketbeat.com

Financial Survey: Revolution Medicines (NASDAQ:RVMD) and Rigel Pharmaceuticals (NASDAQ:RIGL)

November 7, 2026 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $350.00

November 6, 2026 | marketbeat.com

Research Analysts Set Expectations for RVMD FY2029 Earnings

November 6, 2026 | marketbeat.com

Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

November 5, 2026 | finance.yahoo.com

TD Cowen Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

November 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALNY, ARGX, NTRA, and RVMD Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$159.85 +8.21 (+5.41%)

Closing price 04:00 PM Eastern

Extended Trading

$160.68 +0.83 (+0.52%)

As of 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex NASDAQ:ARGX

$977.58 +6.03 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$972.95 -4.63 (-0.47%)

As of 07:48 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Natera NASDAQ:NTRA

$319.82 +7.84 (+2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$321.45 +1.63 (+0.51%)

As of 07:59 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$180.70 -12.36 (-6.40%)

Closing price 04:00 PM Eastern

Extended Trading

$182.40 +1.70 (+0.94%)

As of 07:59 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, ARGX, NTRA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, ARGX, NTRA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, ARGX, NTRA, and RVMD Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

argenex NASDAQ:ARGX

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, ARGX, NTRA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, ARGX, NTRA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, ARGX, NTRA, and RVMD Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

argenex NASDAQ:ARGX

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools